| Literature DB >> 24868201 |
Wu Song1, Yujie Yuan1, Liang Wang1, Weiling He1, Xinhua Zhang1, Chuangqi Chen1, Changhua Zhang1, Shirong Cai1, Yulong He1.
Abstract
Objective. The study was designed to explore the prognostic value of examined lymph node (LN) number on survival of gastric cancer patients without LN metastasis. Methods. Between August 1995 and January 2011, 300 patients who underwent gastrectomy with D2 lymphadenectomy for LN-negative gastric cancer were reviewed. Patients were assigned to various groups according to LN dissection number or tumor invasion depth. Some clinical outcomes, such as overall survival, operation time, length of stay, and postoperative complications, were compared among all groups. Results. The overall survival time of LN-negative GC patients was 50.2 ± 30.5 months. Multivariate analysis indicated that LN dissection number (P < 0.001) and tumor invasion depth (P < 0.001) were independent prognostic factors of survival. The number of examined LNs was positively correlated with survival time (P < 0.05) in patients with same tumor invasion depth but not correlated with T1 stage or examined LNs >30. Besides, it was not correlated with operation time, transfusion volume, length of postoperative stay, or postoperative complication incidence (P > 0.05). Conclusions. The number of examined lymph nodes is an independent prognostic factor of survival for patients with lymph node-negative gastric cancer. Sufficient dissection of lymph nodes is recommended during surgery for such population.Entities:
Year: 2014 PMID: 24868201 PMCID: PMC4020362 DOI: 10.1155/2014/603194
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Overall survival univariate analysis for predictive factors of survival.
| Variables | Number, | Survival, Mo |
|
|
|---|---|---|---|---|
| Gender | 0.912 | 0.364 | ||
| Male | 205 (68.3%) | 51.2 ± 27.3 | ||
| Female | 95 (31.7%) | 48.5 ± 26.7 | ||
| Age (years) | 2.562 | 0.195 | ||
| <60 | 172 (57.3%) | 45.5 ± 24.6 | ||
| ≥60 | 128 (42.7%) | 50.7 ± 30.1 | ||
| Tumor Size (cm) | 0.352 | 0.624 | ||
| <4 | 185 (61.7%) | 50.4 ± 27.2 | ||
| ≥4 | 115 (38.3%) | 46.5 ± 23.4 | ||
| Tumor Location | 4.256 | 0.405 | ||
| Upper third | 42 (14.0%) | 42.2 ± 27.7 | ||
| Middle third | 52 (17.3%) | 46.4 ± 27.2 | ||
| Lower third | 206 (68.7%) | 48.8 ± 32.7 | ||
| T Category | 41.012 | <0.001 | ||
| T1 | 90 (30.0%) | 46.1 ± 29.1 | ||
| T2 | 55 (18.3%) | 48.9 ± 31.2 | ||
| T3 | 117 (39.0%) | 53.0 ± 31.0 | ||
| T4 | 38 (12.7%) | 55.0 ± 31.4 | ||
| Histopathological type | 15.375 | 0.079 | ||
| Adenocarcinoma | 249 (83.0%) | 41.3 ± 25.5 | ||
| Mucinous adenocarcinoma | 21 (7.0%) | 44.3 ± 18.4 | ||
| Signet ring cell carcinoma | 30 (10.0%) | 49.5 ± 14.5 | ||
| Histopathological grading | 25.654 | 0.125 | ||
| Well/medicate differentiated | 199 (66.3%) | 53.2 ± 24.7 | ||
| Poor/undifferentiated | 101 (33.7%) | 46.2 ± 26.7 | ||
| Examined Lymph nodes, | 46.23 | <0.001 | ||
| 1–15 | 74 (24.7%) | 43.7 ± 28.0 | ||
| 16–20 | 53 (17.7%) | 48.4 ± 25.5 | ||
| 21–25 | 45 (15.0%) | 52.7 ± 32.8 | ||
| 26–30 | 36 (12.0%) | 62.0 ± 31.3 | ||
| ≥30 | 92 (30.6%) | 49.7 ± 31.8 |
Data in survival present with median ± SD. Chi-square test was used to compare the categorical variables. P < 0.05 considered statistically significant.
Correlation between number of examined lymph nodes and clinical outcomes.
| Variables | Overall | Number of examined lymph nodes |
|
| ||||
|---|---|---|---|---|---|---|---|---|
| 1–15 | 16–20 | 21–25 | 26–30 | >30 | ||||
| Hospital stay, day | 15.0 ± 6.5 | 12.0 ± 5.5 | 13.5 ± 4.8 | 14.1 ± 6.5 | 16.1 ± 6.2 | 15.5 ± 4.8 | 0.431 | 0.634 |
| Transfusion volume, ML | 207.4 ± 400.4 | 188.3 ± 200.4 | 166.0 ± 66.9 | 120 ± 253.6 | 213.9 ± 398.7 | 248 ± 453 | 0.536 | 0.571 |
| Operation time, min | 266.3 ± 68.5 | 201.3 ± 56.4 | 266.3 ± 166.0 | 274.9 ± 57.5 | 273.3 ± 72.2 | 265 ± 72 | 0.576 | 0.621 |
| Postop. Complication, | ||||||||
| No | 288 (96.0%) | 72 (97.3%) | 51 (96.2%) | 43 (95.6%) | 34 (94.4%) | 88 (95.7%) | 3.423 | 0.228 |
| Yes | 12 (4.0%) | 2 (2.7%) | 2 (3.8%) | 2 (4.4%) | 2 (5.6%) | 4 (4.3%) | ||
Data present as mean ± SD without specific statement. Postop: postoperative; chi-square test was performed to compare differences.
Prognostic factors retained in multivariate analysis.
| Factors |
| Relative risk | 95% CI |
|---|---|---|---|
| Invasion depth | <0.001 | 1.704 | 1.418–2.048 |
| No. of examined lymph nodes | <0.001 | 1.616 | 1.468–1.779 |
Cox proportional hazard analysis was used to investigate the potential prognostic factors of survival in GC patients without lymph node metastasis.
A stratified analysis between examined LNs and survival rate in all patients.
|
| 1–15 | 16–20 | 21–25 | 26–30 | >30 |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ST |
| ST |
| ST |
| ST |
| ST | |||
| T1 | 90 | 21 | 47.3 ± 28.9 | 17 | 49.8 ± 26.2 | 12 | 53.8 ± 18.8 | 14 | 54.1 ± 32.8 | 26 | 55.3 ± 32.3 | 0.06 |
| T2 | 55 | 10 | 43.5 ± 29.3 | 13 | 44.1 ± 24.8 | 8 | 47.3 ± 47.1 | 6 | 55.0 ± 34.4 | 18 | 47.1 ± 25.2 | 0.002 |
| T3 | 118 | 31 | 47.5 ± 27.4 | 15 | 51.8 ± 26.3 | 18 | 57.8 ± 35.4 | 14 | 71.0 ± 22.8 | 42 | 50.0 ± 33.5 | 0.000 |
| T4 | 37 | 12 | 40.1 ± 41.0 | 8 | 48.2 + 14.1 | 9 | 50.2 ± 23.3 | 2 | 71.1 ± 35.5 | 6 | 46.8 ± 36.3 | 0.000 |
|
| ||||||||||||
| Sum | 300 | 74 | 43.7 ± 28.0 | 53 | 48.4 ± 25.5 | 45 | 52.7 ± 32.8 | 36 | 62.0 ± 31.3 | 92 | 49.7 ± 31.8 | 0.000 |
ST: survival time (month for unit); P < 0.05 indicated a statistical significance by one-way ANOVA test.